Here are the latest stories being discussed in biopharma today:
Trodelvy Fails Phase III Lung Cancer Study Shaking Gilead’s ADC Plans
Gilead’s Trodelvy has disappointed in a Phase III trial for non-small cell lung cancer, leading to a 10% drop in the company’s stock. This failure places greater scrutiny on similar offerings from AstraZeneca and Daiichi Sankyo’s TROP2 ADC that have also shown lacklustre results in similar patient populations.
Hibernation Research Points Towards Potential Weight Loss Medicines
New developments in hibernation research could change the landscape of weight-loss medications — there’s even potential benefits for astronauts in space.
Dimmed Results for Alzheimer’s Drugs End Roche-AC Immune Partnership
In the wake of uninspiring results for Alzheimer’s drugs, Roche and AC Immune have decided to terminate their partnership.
Ionis Celebrates Phase III Success Amid Independent Commercialization Drive
Ionis Pharmaceuticals is in high spirits following a successful Phase III outcome for a rare disease drug, marking a crucial milestone in their push to commercialize drugs independently.
Cara Announces Employee Layoffs to Preserve Funds, Ends Phase III Kidney Disease Program
In a bid to extend its cash runway, Cara Therapeutics is laying off workers and halting a Phase III program for chronic kidney disease.
Biotech News Roundup: Positive Phase IIb NASH Data from Sagimet, FDA lifts Hold on Pharvaris IND, Dianthus Raises $230M
Interesting biotech news this week includes Sagimet’s promising Phase IIb data for NASH, the FDA lifting the hold on Pharvaris IND, and Dianthus scoring a hefty $230M fund raise.
Merger of Two Biotechs to Form Calluna, Backed by €75M for Immunotherapy Antibodies
Two biotechnology firms are merging to form Calluna, with €75 Million in funding to focus on the development of antibody-based immunotherapies.
ArriVent Intends to Raise $135M in Second Biotech IPO of 2024
ArriVent is planning for a $135 Million IPO, marking the second biotech listing of 2024.
Pfizer, Biohaven Veteran Takes the Helm as Apnimed’s First Chief Commercial Officer
Apnimed has hired a seasoned Pfizer and Biohaven executive as the company’s first Chief Commercial Officer.
Coherus Sells its Lucentis Biosimilar to Sandoz for $170M to Concentrate on Oncology Assets
Coherus BioSciences has confirmed the sale of its Lucentis biosimilar to Sandoz for $170 Million, as Coherus shifts its focus to oncology assets.
Healthcare Connector LunaDNA Shuts Down Operations
LunaDNA, a platform that facilitates connections between patients and pharmaceutical firms, has stated its intent to shutter its operations.
